We previously demonstrated increased glucagon-like peptide-1 (GLP-1) secretion during acute ST elevation myocardial infarction (STEMI) in non-diabetic (ND) patients. Whether the endogenous GLP-1 system response is different in patients with type 2 diabetes (T2D) during STEMI is unknown. Patients with STEMI (20 ND, 13 T2D) and 3 control groups (non-STEMI [14 ND, 13 T2D], stable angina pectoris [SAP] [8 ND, 10 T2D] patients and healthy subjects) (n = 25) were studied. Plasma levels of total and active GLP-1 and soluble dipeptidyl peptidase-4 (sDPP4) were estimated by enzyme-linked immunosorbent assay on admission and at 24 and 48 hours after percutaneous coronary intervention in all patients. Sharply elevated levels of total and active GLP-1 were found in ND STEMI patients at 24 h (P < 0.05 and P < 0.005, respectively), but not in T2D
| INTRODUCTION

Pharmacological doses of glucagon-like peptide-1 receptor (GLP-1R)
agonists improve glucose metabolism and cardiovascular outcome in type 2 diabetes (T2D) patients. 1 This suggests that the impaired pancreatic incretin effect in T2D patients 2 is associated with defective extra-pancreatic cardiovascular protection. Increased GLP-1 levels and cardiac GLP-1 receptor expression were reported in patients with impaired systolic left ventricular (LV) function, 3 despite the fact that the cardiac GLP-1R-bearing cell types were not fully identified yet. 4 This suggests that the endogenous GLP-1/GLP-1R system serves as a compensatory mechanism for systolic LV dysfunction. 3 It has been demonstrated that GLP-1R agonists reduce infarct size and increase myocardial salvage in diabetic and non-diabetic patients with ST elevation myocardial infarction (STEMI). 5 However, in addition to intact GLP-1, its metabolites also exert cardio-protection independently from GLP-1R pathway, 6 while the GLP-1 inhibitory enzyme dipeptidyl peptidase-4 (DPP4) directly and indirectly affects the cardiovascular system, 7 albeit with controversial clinical outcome. 1 Thus, intact GLP- show no GLP-1 response on admission and significantly decreased level of total GLP-1 at 24 hours after admission compared with STEMI patients. C, Non-STEMI patients were divided into early and late groups according to admission time to ICCU: 16 AE 1.73 and 74 AE 7.00 hours, respectively. Only early but not late patients show transiently significant increased active GLP-1 at 24 hours after admission compared with healthy controls. D, STEMI ND patients show sharply increased total (black circles) and active (white circles) GLP-1 levels at 24 hours after admission. By contrast, T2D patients show total GLP-1 levels comparable with controls and higher active GLP-1 levels but no further increase at 24 and 48 hours after admission. E, ND non-STEMI patients show total and active GLP-1 levels at admission and at 24 and 48 hours comparable with healthy controls. By contrast, T2D patients show decreased total GLP-1 compared with healthy controls and ND patients and preserved active GLP-1 comparable with controls. Data represent mean AE SE. *, **, ***, **** = P < 0.05, P < 0.005, P < 0.0005, P < 0.00005 vs. healthy controls, respectively; # , ## = P < 0.05, P < 0.05, respectively, vs. a in the same group;^= P < 0.05 vs. b in STEMI ND patients; ˅ = P < 0.05 vs. a in non-STEMI ND patients patients was also significantly higher compared with non-STEMI patients: 32.6 AE 17.7 and 23.5 AE 8.79, respectively (P < 0.05).
Although the baseline characteristics of the study subgroups were comparable (data not shown), STEMI patients were admitted to ICCU earlier than non-STEMI patients (mean 0.8 AE 0.15 and 38 AE 6.38 hours, respectively). Therefore, we compared the GLP-1 levels in non-STEMI patients admitted within the first day (mean 16.3 AE 
| Endogenous GLP-1 response is not upregulated in T2D patients with STEMI
ND STEMI but not ND non-STEMI patients showed sharply increased total and active GLP-1 levels at 24 hours compared with admission time (P < 0.005 and P <0.05, respectively) ( Figure 1D ,E). In contrast to ND patients, T2D patients with STEMI showed higher than control admission levels of active GLP-1 (P < 0.05), which remained unchanged at 24 and 48 hours ( Figure 1D ). T2D non-STEMI patients showed generally lower total and active GLP-1 levels compared with STEMI patients with T2D ( Figure 1D ,E). Inflammatory and myocardial damage markers were comparable in ND and T2D patients (data not shown). DPP4 levels were significantly lower than controls regardless of ACMI type and presence of T2D (P < 0.005) ( Figure S1A ,B, Supporting Information) and associated with significantly increased active/total GLP-1 ratios in all patients compared with controls (P < 0.05, P < 0.005). T2D patients with non-STEMI and SAP showed approximately 2-fold higher ratios compared with controls ( Figure S1C , Supporting Information).
| DISCUSSION
Active GLP-1 levels were higher than controls in patients with acute and chronic ischemic heart disease. However, only the patients with responses rather than an inherent difference related to ACMI type.
Indeed, early but not later admitted non-STEMI patients also showed increased active GLP-1 at 24 hours. Nevertheless, the overall GLP-1 response of non-STEMI patients was still lower than STEMI patients.
The inflammatory response of non-STEMI patients is significantly lower compared with STEMI patients. 10 GLP-1 has anti-inflammatory effects and its secretion is increased in response to inflammatory stimuli in humans. 11 This may suggest that the lower GLP-1 system response in non-STEMI patients may result from their weaker inflammatory stimuli compared with STEMI patients. Although the inflammatory markers, CRP and WBC were comparable in non-STEMI and STEMI patients, the latter showed significantly 3-and 4-fold higher peak troponin and CPK levels, respectively. This may suggest that the magnitude of the GLP-1 system response is associated with the extent of myocardial damage rather than inflammatory state.
The significantly reduced sDPP4 level in all ischaemic heart disease (IHD) patients suggests the existence of incretin dependent and independent adaptive mechanisms to cardiac ischemia which attenuate endothelial dysfunction, inflammation and atherosclerotic process. 12 This is supported by our recent demonstration of sepsisassociated reduced sDPP4 levels. 13 However, loss of DPP4 activity has been linked to a pro-thrombogenic status of endothelial cells and may negatively affect the coronary microvasculature of patients with myocardial infarction 7 and reduced formation of cardio-protective GLP-1 metabolites. 6 Therefore, the exact role of DPP4 reduction in IHD remains to be elucidated.
The most interesting finding of our work relates to the different GLP-1 system response in patients with and without T2D ( metabolites. This is of particular importance as both forms of GLP-1 are required for full cardio-protective effect. 6 Thus, DPP4 inhibitors that reduce the levels of GLP-1 metabolites during ACMI may also be deleterious.
Several small studies showed that exogenous GLP-1 analogues reduce reperfusion injury in patients with STEMI. 5 However, the effect of T2D was not evaluated. Our data may also suggest that treatment of those T2D patients characterized by impaired adaptive GLP-1 response using intact and metabolic GLP-1 forms may be beneficial during ACMI.
The limited size of our cohort did not allow a correlation between GLP-1 response and the clinical outcome. Thus, it remains unknown whether the impaired GLP-1 response in T2D patients with ACMI underlies their worse prognosis. In addition, the significance of glucose intolerance which is common to ACMI patients without previous diabetes history was not evaluated.
In summary, our work demonstrates for the first time that the endogenous GLP-1 system response during ACMI is upregulated in ND but not in T2D patients. Future interventional studies with T2D
patients and STEMI or non-STEMI treated with intact GLP-1 and its metabolites are required to determine the optimal GLP-1-based therapy for these patients.
